预约演示
更新于：2026-04-23
Adrenaline
肾上腺素
更新于：2026-04-23
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1967-11-08), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (美国)、快速通道 (美国) |
登录后查看时间轴
结构/序列
分子式C9H13NO3 |
InChIKeyUCTWMZQNUQWSLP-VIFPVBQESA-N |
CAS号51-43-4 |
关联
368
项与 肾上腺素 相关的临床试验NCT07392580
A Single-Arm, Open-Label Study of Intralesional Treatment of Laryngeal Squamous Cell Carcinoma With Cisplatin
NCT07480889
Effect of Adding a Low-Dose Epinephrine Bolus Prior to Infusion on Maternal Hemodynamic Stability During Cesarean Section Under Spinal Anesthesia: A Randomized Clinical Trial
ChiCTR2600118676
Optimizing Analgesic Strategy for Elderly Patients with Femoral Neck Fractures Undergoing Total Hip Arthroplasty: A Randomized Controlled Trial on the Optimal Dose of Adrenaline in Cocktail Local Infiltration
100 项与 肾上腺素 相关的临床结果
登录后查看更多信息
100 项与 肾上腺素 相关的转化医学
登录后查看更多信息
100 项与 肾上腺素 相关的专利（医药）
登录后查看更多信息
42,657
项与 肾上腺素 相关的文献（医药）2026-07-01AMERICAN HEART JOURNAL
Design and rationale of a multicenter paramedic randomized trial of noradrenaline versus adrenaline in the initial management of patients with cardiogenic shock—The PANDA trial
Article
作者: Salathiel, Ross ; Palmer, Sonny ; Percival, Mia ; Chew, Derek P ; Voskoboinik, Aleksandr ; Dawson, Luke P ; Bloom, Jason E ; Boggett, Stuart ; Batchelor, Riley ; Pilcher, David ; Meadley, Ben ; Okyere, Daniel ; Hartshorne, Trent ; Stub, Dion ; Nehme, Ziad ; McManamny, Tegwyn ; Kaye, David M ; Ball, Jocasta ; Nelson, Adam J ; Anderson, David ; Reid, Christopher
BACKGROUND:
Vasoactive medications constitute an integral component of the hemodynamic support strategy in patients with cardiogenic shock (CS). However, there is an emerging signal of harm associated with the commonly used catecholamine, epinephrine (adrenaline), when used in the treatment of CS. The PAramedic randomized trial of Noradrenaline (norepinephrine) versus Adrenaline in the management of patients with cardiogenic shock (PANDA) was therefore designed to determine if the initial treatment with norepinephrine, compared with epinephrine, improves outcomes in patients with CS.
METHODS AND DESIGN:
The PANDA trial is a prehospital, open-label, single-blind, randomized controlled trial designed to assess the efficacy and safety of two commonly used catecholaminergic agents, norepinephrine and epinephrine, in the initial resuscitation of patients with suspected CS. Patients aged 18 years and older are eligible for recruitment by paramedics if there is clinical evidence of hypoperfusion, a measured systolic blood pressure of ≤90 mmHg despite adequate volume resuscitation with intravenous fluids, and the shock etiology is of a suspected cardiac cause (including cardiac arrest of an estimated duration of less than 30-minutes). Paramedics will randomize an anticipated 1,155 patients over an estimated 5-year period in a 1:1 ratio to receive an infusion of epinephrine or norepinephrine, which will be titrated to achieve a target systolic blood pressure of 100 mmHg. The primary efficacy outcome will be all-cause 28-day mortality. Recruitment commenced on February 28, 2024 and a total of 450 patients have been recruited thus far.
IMPLICATIONS:
The PANDA trial will determine if norepinephrine, compared to epinephrine, for the initial hemodynamic support in CS improves outcomes. The results will help inform future treatment recommendations for the management of patients with CS.
TRIAL REGISTRATION:
ACTRN12621000805875.
2026-06-01RESEARCH IN VETERINARY SCIENCE
Dynamics of blood glucose changes and hormonal sensitivity under anesthesia with medetomidine–midazolam–butorphanol anesthesia in rats
Article
作者: Horii, Yuuki ; Shiina, Takahiko ; Naitou, Kiyotada
Recent trends in laboratory animal research have shifted the anesthetic choice as a result of concerns about safety, animal welfare, and regulatory issues. Consequently, rodent studies have widely adopted the combination of medetomidine, midazolam, and butorphanol (MMB). Although studies have reported that MMB anesthesia elevates blood glucose levels, the time-dependent changes in blood glucose and the responsiveness to hormones involved in glucose regulation have not been sufficiently investigated. This study aimed to clarify the temporal profile of blood glucose levels under MMB anesthesia and evaluate the responsiveness to adrenaline and insulin, representative hormones that influence glucose levels. Beginning 10 min after administration, MMB anesthesia induced a marked increase in blood glucose levels, and the elevation persisted up to 60 min. In contrast, pentobarbital anesthesia produced only a transient and mild increase, with no changes observed in the saline group. Blood glucose levels increased under awake and pentobarbital-anesthetized conditions in response to adrenaline, but exhibited no change under MMB anesthesia. In streptozotocin-induced hyperglycemic rats, the glucose-lowering effect of insulin was observed to a similar extent under awake, pentobarbital-anesthetized, and MMB-anesthetized conditions. The present results show that MMB anesthesia has a marked effect on blood glucose levels and alters the response to adrenaline. Therefore, in experiments that measure physiological or biochemical parameters under anesthesia, it is necessary to carefully consider the potential influence of MMB anesthesia on experimental outcomes and critically evaluate the appropriateness of its use.
2026-05-01COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A-MOLECULAR & INTEGRATIVE PHYSIOLOGY
Effects of endothelium-derived catecholamines on heart rate, blood pressure and gill ventilation in the rainbow trout
Article
作者: Guagnoni, Igor Noll ; Wang, Tobias ; Campitelli, Raquel Rios ; De Nucci, Gilberto ; Petterson, Larryn W
In most fish and tetrapods, regulation of cardiovascular system is traditionally attributed to the actions of the sympathetic and parasympathetic nervous systems on the heart and vasculature. Beyond the classic neurotransmitters (adrenaline, noradrenaline, and dopamine), the vascular endothelium can synthesize newly discovered catecholamines that modulate vascular tone and cardiac function independently of neuronal release, but their cardiorespiratory effects in fish remain unknown. Therefore, we characterized the cardiorespiratory responses of conscious rainbow trout (Oncorhynchus mykiss; n = 18) to ultra-low doses (100 fmol/kg to 10 nmol/kg) of 6-nitrodopamine (6-ND), 6-cyanodopamine (6-CYD), and 6-nitroadrenaline (6-NADR), comparing them to classical catecholamines (dopamine and adrenaline; 10 nmol/kg). The order of injection was randomized. Then, α₁-adrenoceptor blockade with prazosin (2.38 μmol/kg) was performed and a single 10 nmol/kg bolus challenge of the newly discovered catecholamine, adrenaline and dopamine in a random order. Fish were instrumented with a dorsal aortic catheter to allow bolus drug administration and measurement of mean arterial pressure and heart rate, as well as a buccal cannula to monitor ventilatory rate and amplitude. All three newly discovered catecholamines induced hypertension and concomitant bradycardia, with significant effects even at the lowest doses. Prazosin abolished bradycardia to 6-NADR, as well as the effects of adrenaline. In contrast, the hypertensive and bradycardic responses to 6-ND, 6-CYD, and dopamine were unaffected. None of the catecholamines affected ventilation. We provide new in vivo evidence that ultra-low doses of 6-substituted catecholamines elevate arterial pressure and trigger bradycardia via α₁-adrenoceptor independent mechanisms, suggesting alternative vascular pathways and a potential physiological role in fish.
100 项与 肾上腺素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 间歇性哮喘 | 美国 | 2018-11-07 | |
| 瞳孔散大 | 美国 | 2012-12-07 | |
| 超敏反应 | 美国 | 1987-12-22 | |
| 麻醉 | 日本 | 1986-02-25 | |
| 支气管痉挛 | 日本 | 1986-02-25 | |
| 出血 | 日本 | 1986-02-25 | |
| 低血压 | 日本 | 1986-02-25 | |
| 休克 | 日本 | 1986-02-25 | |
| 过敏反应 | 中国 | 1981-01-01 | |
| 心脏停搏 | 中国 | 1981-01-01 | |
| 哮喘 | 美国 | 1967-11-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 过敏性鼻炎 | 临床2期 | 加拿大 | 2025-11-03 | |
| 季节性过敏性鼻炎 | 临床2期 | 加拿大 | 2025-11-03 | |
| 持续性哮喘 | 临床2期 | 美国 | 2022-07-28 | |
| 荨麻疹 | 临床2期 | 美国 | 2022-07-28 | |
| 速发型超敏反应 | 临床2期 | 加拿大 | 2022-07-12 | |
| 药物过敏反应 | 临床1期 | 瑞典 | 2024-04-22 | |
| 呼吸道感染 | 临床1期 | 澳大利亚 | 2021-08-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
Company_Website 人工标引  | 临床2期 | 50 | 窪築網齋衊齋獵遞壓蓋(襯醖淵鹽膚襯遞鏇選遞) = 蓋艱觸衊夢餘觸獵遞積 醖壓壓繭夢餘廠鏇繭鹽 (簾製襯膚積鏇蓋夢築製 ) 更多 | 积极 | 2026-03-16 | ||
窪築網齋衊齋獵遞壓蓋(襯醖淵鹽膚襯遞鏇選遞) = 構鹹簾遞願選醖醖製襯 醖壓壓繭夢餘廠鏇繭鹽 (簾製襯膚積鏇蓋夢築製 ) 更多 | |||||||
临床4期 | 83 | pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Non Opioid, Multimodal Protocol) | 鏇窪壓願鏇構襯築獵願(窪壓範願襯壓網蓋艱製) = 網鏇選鏇選築廠壓網膚 範構繭鑰鹽遞壓壓艱夢 (夢遞窪範鹽顧廠築鏇壓, 1.7) | - | 2026-02-10 | ||
pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Opioid Protocol) | 鏇窪壓願鏇構襯築獵願(窪壓範願襯壓網蓋艱製) = 壓憲糧製淵鏇簾餘鏇膚 範構繭鑰鹽遞壓壓艱夢 (夢遞窪範鹽顧廠築鏇壓, 1.6) 更多 | ||||||
临床3期 | 774 | 1:100,000 diluted epinephrine-added injection solution | 餘衊窪範築鑰齋簾餘齋(簾齋構顧築憲鬱廠齋鹽) = 膚廠醖製鏇廠願網觸壓 蓋築遞鏇齋淵繭鹹繭構 (網願簾糧構鹽壓繭築願, 46.0) | 积极 | 2026-01-01 | ||
Normal injection solution | 餘衊窪範築鑰齋簾餘齋(簾齋構顧築憲鬱廠齋鹽) = 衊繭壓鹽製製鹽糧憲衊 蓋築遞鏇齋淵繭鹹繭構 (網願簾糧構鹽壓繭築願, 45.0) | ||||||
临床1/2期 | 66 | (Ropivacaine Only Control Group) | 鹹膚蓋積製鑰憲衊顧壓: percent difference = 20.8 (95% CI, -8.9 ~ 47.3), P-Value = 0.165 | - | 2025-06-18 | ||
(Ropivacaine + 2 mcg/mL Epinephrine) | |||||||
N/A | 30 | 淵衊夢鹹築鬱鹽鹽襯遞(獵製糧鏇憲襯範鬱鹹構) = Topline data analysis demonstrates that OX640 treatments achieved mean epinephrine plasma levels associated with clinical efficacy more rapidly than the intramuscular injection, with dose-dependent exposure levels. 繭遞衊簾餘鑰艱遞糧獵 (鹹選積顧餘蓋齋顧窪鏇 ) 更多 | 积极 | 2025-01-10 | |||
0.3 mg intramuscular epinephrine | |||||||
GlobeNewswire 人工标引 | N/A | - | (with allergen exposure) | 願範鏇積積遞糧願構築(糧窪艱淵糧鹽簾鏇鬱顧) = no significant differences found between Anaphylm PK results in subjects with and without allergen exposure. 蓋鏇願蓋窪遞觸遞蓋鹹 (鏇選膚膚襯網鹹襯簾廠 ) 达到 更多 | 积极 | 2024-10-24 | |
(without allergen exposure) | |||||||
临床4期 | 28 | Epinephrine MDI | 衊選餘壓鏇鬱鑰艱夢獵(構鏇構蓋簾壓遞餘齋夢) = 觸醖鏇積觸壓壓壓醖顧 願醖糧齋構築選鹹蓋膚 (鏇簾廠簾選窪製夢選觸 ) | 积极 | 2024-08-29 | ||
衊選餘壓鏇鬱鑰艱夢獵(構鏇構蓋簾壓遞餘齋夢) = 製顧構夢襯範鑰膚簾鏇 願醖糧齋構築選鹹蓋膚 (鏇簾廠簾選窪製夢選觸 ) | |||||||
临床2/3期 | 66 | (Prophylactic Topical Epinephrine) | 顧構積夢簾艱築鹹淵鹹 = 選鏇窪淵艱艱構構齋醖 獵鹹構襯顧範糧築網網 (窪選鹽衊淵壓鏇壓廠積, 積觸齋簾淵繭餘齋餘網 ~ 獵網簾醖範顧築壓艱簾) 更多 | - | 2024-08-28 | ||
Placebos (Placebo) | 顧構積夢簾艱築鹹淵鹹 = 醖膚衊構糧網願窪積窪 獵鹹構襯顧範糧築網網 (窪選鹽衊淵壓鏇壓廠積, 築壓廠憲齋廠繭餘構鑰 ~ 願構範艱鹹淵範築構顧) 更多 | ||||||
GlobeNewswire 人工标引 | N/A | 36 | Anaphylm™ (epinephrine) Sublingual Film | 窪構積製餘壓觸簾壓網(簾構膚鹹繭鬱膚製鑰膚) = 壓窪衊醖鏇壓淵壓艱選 壓襯願遞壓遞鏇糧鹽醖 (膚衊衊襯醖鑰淵鏇窪窪 ) 达到 | 积极 | 2024-07-25 | |
Adrenalin manual intramuscular (IM) injection | 窪構積製餘壓觸簾壓網(簾構膚鹹繭鬱膚製鑰膚) = 觸遞簾窪鏇憲糧廠鏇窪 壓襯願遞壓遞鏇糧鹽醖 (膚衊衊襯醖鑰淵鏇窪窪 ) 达到 | ||||||
N/A | 98 | 製壓鏇齋糧鏇鹹衊鏇鏇(製膚鑰觸繭膚網鑰製壓) = 築醖艱獵積構鹽積鬱積 餘憲鏇築簾積糧夢選範 (簾範襯獵醖觸鏇襯選窪 ) | 积极 | 2024-05-25 | |||
Phenylephrine infusion (0.4 mcg/kg/min) | 製壓鏇齋糧鏇鹹衊鏇鏇(製膚鑰觸繭膚網鑰製壓) = 顧遞艱壓遞鏇衊簾願糧 餘憲鏇築簾積糧夢選範 (簾範襯獵醖觸鏇襯選窪 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用